SEPSIS: GUIDELINES FOR CURRENT MANAGEMENT JONATHAN R. HIATT, MD DEPARTMENT OF SURGERY THE DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA

Transcription

1 SEPSIS: GUIDELINES FOR CURRENT MANAGEMENT JONATHAN R. HIATT, MD DEPARTMENT OF SURGERY THE DAVID GEFFEN SCHOOL OF MEDICINE AT UCLA

2 Definitions Scoring systems Surviving Sepsis Campaign Evaluation of evidence Management guidelines

3 SYNDROMES Systemic SIRS inflammatory response MODS Multiple organ dysfunction

4 DEFINITIONS Inflammation (fever, leukocytosis) SIRS + infection Sepsis + multiorgan dysfunction Severe sepsis + refractory hypotension SIRS Sepsis Severe sepsis Septic shock

5 SIRS: CLINICAL CRITERIA Any two or more: Body temperature Heart rate Respiratory rate Hyperventil. (PaCO 2 ) WBC Immature polys > 38 or < 36 > 90 > 20 < 32 > 12K or < 4K > 10% Chest 92

6 SIRS: CAUSES Infection Intestinal endotoxin Ischemia Multisystem trauma Noxious substances Shock Thermal injury Chest 92

7 MODS Lungs Kidneys Cardiovascular CNS PNS Coagulation GI tract Liver Adrenals Skeletal muscle Acute respiratory distress synd. Acute tubular necrosis Hyperdynamic hypotension Metabolic encephalopathy Polyneuropathy of crit. illness Disseminated intravasc. coag. Gastroparesis / ileus Acute noninfectious hepatitis Acute adrenal insufficiency Rhabdomyolysis

8 CLINCAL SCORING SYSTEMS APACHE II Acute Physiology & Chronic Health Evaluation ICU adm. MODS Multiple Organ Dysfunction Score Daily GCS Glasgow Coma Scale Dynamic

9 SURVIVING SEPSIS CAMPAIGN Multinational expert committee Barcelona Declaration (2002) International Sepsis Forum (2001) 14 year MEDLINE review ( ) Grading Evidence Recommendations Total consensus in all but 2 recs. *(steroids, antibiotics) Dellinger, CCM 04

10 Level SEPSIS MANAGEMENT GRADING OF EVIDENCE I II III IV V Large randomized trials Small randomized trials Nonrandom., contemp. controls Nonrandom., historical controls Case series; uncontr.; expert opinion

11 GRADING OF RECOMMENDATIONS Grade A B C D E Support At least 2 level I investigations One level I investigation Level II investigations only At least 1 level III investigation Level IV or V evidence Dellinger, CCM 04

12 GRADES IN GUIDELINES (n=52) n % A At least 2 level I investigations 5 10 B One level I investigation C Level II investigations only 5 10 D At least 1 level III investigation 4 8 E Level IV or V evidence Dellinger, CCM 04

13 Definitions Scoring systems Surviving Sepsis Campaign Evaluation of evidence Management guidelines

14 INITIAL RESUSCITATION For severe sepsis or hypoperfusion (hypotension or lactic acidosis) Normotensive: Elevated lactate identifies hypoperfusion Begin immediately Do not delay for ICU admission 1st 6 hours: Goals and interventions

15 INITIAL RESUSCITATION First 6-hour goals: CVP 8-12 MAP > 65 Urine > 0.5 ml/kg/hr O 2 sat (CV or MV) > 70% If O 2 sat < 70% with CVP 8-12: PRBC to Hct > 30 and/or Dobutamine (up to 20? g/kg/min)

16 DIAGNOSIS Cultures before antibiotics At least two blood cultures Percutaneous Each vasc access device unless inserted within 48 hrs. Diagnostic studies Unless unstable for transport Consider bedside tests (sono)

17 ANTIBIOTIC THERAPY Initiation Regimen Empiric Specific (focused) Cessation

18 ANTIBIOTIC THERAPY Initiation: within one hour Empiric regimen Initial broad spectrum Active ag. likely pathogens Penetrate likely site Consider local susceptibility patterns Hepatic, renal function affect dosing Cessation if noninfectious cause

19 FOCUSED ANTIBIOTIC REGIMEN Reassess after hrs Cultures guide therapy Narrow spectrum agent Resistance, toxicity, costs Course: 7 10 days Monotherapy, not combination *Possible exception: Pseudomonas Definite exception: Neutropenia

20 NOSOCOMIAL SEPTICEMIA Organism Gram neg. enterics Coag. neg. staph Staph aureus Enterococci Streptococci Anaerobes Candida species Other % Source Pneumonia Vasc. catheters Pneumonia Pneumonia Unknown Pneumonia Vasc. catheters Mult. sources Pittet, JAMA 94

21 SOURCE CONTROL Search for treatable focus Multidisciplinary approach Interventions: Consider risks / benefits Intervene early after resuscitation Vascular access devices: Common sources of bacteremia If potential source: Establish alternate access, remove early

22 CATHETER SEPTICEMIA Organism % S. epi. 27 S. aureus 26 Candida 17 Klebs. 11 Serratia 5 Pseud. 3 Other 8 13 prosp. studies S.Clin.N.Am 1988 Guidewire exchange Suspected infection Aseptic placement New site Infected site (red, pus) Infected tip (> 15 cfu) Marino, The ICU Book

23 SOURCE CONTROL Technique Drainage Debridement Device removal Definitive control Examples Intra-abd. abscess; empyema; septic arthritis; pyelo; cholangitis Necrotizing fasciitis; pancreatic necrosis/abscess; mediastinitis Infected vascular catheter; urinary catheter; ET tube; IUD Sigmoid resection (diverticulitis); cholecystectomy; amputation for clostridial myonecrosis

24 Colloid or crystalloid Crystal: Fluid challenge FLUID THERAPY volumes, edema; cost Crystal: ml Colloid: ml Infuse over 30 min Repeat based on response, tolerance

25 VASOPRESSORS Indication: BP, perfusion despite fluids Route: through central line Agent: norepinephrine or dopamine No low-dose dopa for renal protection Arterial catheter for monitoring Refractory shock: vasopressin u/m

26 Indication: Low CO despite fluids Agent: Dobutamine Low BP: combine with vasopressors Goals: SEPSIS MANAGEMENT INOTROPIC THERAPY Arbitrary elevated level not advised (A) Adequate oxygen delivery Avoid flow-dependence

27 O 2 EXTRACTION - DELIVERY

28 ARTERIAL OXYGEN CONTENT CaO = (1.34 x Hb x 2 SaO ) 2 + (0.003 x PaO ) 2 = 1.34 x 15 x 0.98 = 19.7 ml/100 ml

29 OXYHEMOGLOBIN DISSOCIATON CURVE

30 OXYGEN DELIVERY DO 2 = Q x CaO 2 = Q x (1.34 x Hb x SaO 2 ) x 10 = 5 x 19.7 x 10 = 985 ml/min = ml/min/m 2

31 OXYGEN EXTRACTION VO 2 = Q x 13.4 x Hb x (SaO 2 - SvO 2 ) = 5 x 13.4 x 15 x ( ) = 229 ml/min = ml/min/m 2

32 OXYGEN EXTRACTION RATIO O 2 ER = VO 2 / DO 2 = 110 / 520 =

33 O 2 EXTRACTION - DELIVERY

34 STEROIDS Indication: septic shock requiring pressors despite adequate fluids Agent: Hydocortisone IV mg/day 3 or 4 divided doses 7-day course * Consider: ACTH stimulation test ACTH 250? g IV Measure cortisol min Responder: increase 9? g/dl

35 STEROIDS FOR SEPTIC SHOCK Consider taper at end of therapy Consider fludrocortisone (50? g PO qid) Hydrocortisone > 300 mg/day not indicated (A) No shock: steroids not indicated Maintenance or stress dose steroids: no contraindication

36 RECOMBINANT HUMAN ACTIVATED PROTEIN C (rhapc) Endog. anticoagulant, anti-inflammatory Rationale: coagulation, endothelial activation in septic inflam. response Improved survival (Bernard, NEJM 2001) Recommended: APACHE II > 25 Sepsis-induced MOF, shock, or ARDS No contraindications

37 rhapc IN SURGICAL PATIENTS 28% of 850 PROWESS patients Mortality risk reduction: All surgical pts.: 3.2% Intra-abdominal procedures: 9.1% Bleeding: Barie, Am J Surg 04

38 rhapc: CONTRAINDICATIONS Active internal bleeding Recent (3 mos) hemorrhagic stroke Recent (2 mos): Intracranial operation Intraspinal operation Severe head trauma Trauma with increased bleeding risk Epidural catheter Intracranial neoplasm, mass, herniation

39 BLOOD PRODUCTS PRBC for Hgb < 7 g/dl Erythropoietin not indicated FFP: bleeding, invasive procedures Antithrombin not indicated Platelet transfusion: Counts < ,000 w significant risk of bleeding > 50,000 for surgery / invasive proced.

40 ALI / ARDS: MECHANICAL VENT. Reduced tidal volumes (6 ml/kg) Plateau pressure < 30 cm H 2 O Permissive hypercapnia acceptable PEEP to prevent end-expir. collapse Consider prone positioning Elevate HOB 45 0 (prevents pneumonia) Use weaning protocol

41 PLATEAU PRESSURE P plat : small airways pressure in PPV Cause of ventilator-induced lung injury

42 Arousable SEPSIS MANAGEMENT WEANING CRITERIA Stable hemodynamics off pressors No new potentially-serious conditions Low vent., PEEP requirements F i O 2 deliverable by mask or prongs Spontaneous breathing trial (A) (CPAP or T-piece)

43 SPECIFIC WEANING CRITERIA Parameter PaO 2 / FiO 2 Tidal volume Resp. rate Vital capacity Min. ventilation Max. insp. press. Rate / tidal vol. Nl. adult range > ml/kg / min ml / kg 5-7 L / min Greater predictive value >-90 cm H 2 O (F) >-120 cm H 2 O (M) < 50 / min / L Wean. threshold ml / kg < 40 / min 10 ml / kg < 10 L / min - 25 cm H 2 O < 100 / min / L Marino, The ICU Book

44 CLINICAL CRITERIA FOR ARDS Parameter Onset Clinical setting Gas exchange Chest x-ray Wedge pressure ARDS Acute Predisposing condition PaO 2 / FiO 2 < 200 regardless of PEEP level Bilateral infiltrates < 18 mm Hg

45 ARDS

46 ARDS WEANING TRIAL

47 ARDSNET PROTOCOL NEJM 00

48 SEDATION PROTOCOLS Required in critical illness Sedation goals Set end-points Measured by standard subjective scales Bolus or continuous infusion Daily awakening / retitration Reduce vent. duration, LOS, trach rate

49 NEUROMUSCULAR BLOCKERS Avoid if possible Bolus or continuous infusion Train of four monitoring Risk: prolonged muscle weakness

50 GLUCOSE CONTROL Maintain blood glucose < 150 mg/dl Continuous insulin / glucose Glucose monitoring Initiation: q min Maintenance: q 4 hr Enteral nutrition preferred

51 RENAL REPLACEMENT Hemodialysis, continuous venovenous hemofiltration (CVVH) equivalent Unstable hemodynamics: CVVH Dialysis Ultrafiltration

52 BICARBONATE THERAPY Not recommended for treatment of hypoperfusion-induced lactic acidemia with ph > 7.15

53 DVT PROPHYLAXIS Recommended for severe sepsis (A) Agent: Low-dose unfractionated heparin or LMWH Compression stockings if heparin contraindicated Very high risk (DVT hx): combination

54 STESS ULCER PROPHYLAXIS Recommended for severe sepsis (A) H 2 receptor antagonists preferred H 2 RA better than sucralfate PPI: equivalent gastric ph effects but not assessed vs. H 2 RI

55 LIMITATION OF SUPPORT Advance care planning advised Discussion with patient and family Likely outcomes Realistic goals of treatment Consider patient s best interest: Less aggressive therapy Withdrawal of support

56 SUMMARY Practice guidelines Evidence-based Source control Physiologic basis